RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families
暂无分享,去创建一个
Á. Carracedo | S. Bonache | O. Díez | S. Gutiérrez‐Enríquez | J. Balmaña | A. Vega | M. Santamariña | G. Montalban | A. Blanco
[1] Jian-Bing Fan,et al. Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status , 2014, Scientific Reports.
[2] A. Meindl,et al. RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families , 2013, Breast Cancer Research.
[3] Sheena M. Scroggins,et al. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.
[4] R. Rouzier,et al. Germline RAD51C mutations in ovarian cancer susceptibility , 2013, Clinical genetics.
[5] R. Berger,et al. Germline mutations in RAD51C in Jewish high cancer risk families , 2012, Breast Cancer Research and Treatment.
[6] A. Meindl,et al. Germline RAD51C mutations confer susceptibility to ovarian cancer , 2012, Nature Genetics.
[7] F. Couch,et al. Mutation screening of RAD51C in high-risk breast and ovarian cancer families , 2012, Familial Cancer.
[8] J. Benítez,et al. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. , 2012, Human molecular genetics.
[9] M. Blok,et al. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing , 2012, Breast Cancer Research and Treatment.
[10] Samantha E. Boyle,et al. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients , 2012, Hereditary Cancer in Clinical Practice.
[11] Y. Bignon,et al. CHEK2 contribution to hereditary breast cancer in non-BRCA families , 2011, Breast Cancer Research.
[12] Rochelle L. Garcia,et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.
[13] Susan L. Neuhausen,et al. RAD51C Germline Mutations in Breast and Ovarian Cancer Cases from High-Risk Families , 2011, PloS one.
[14] J. Schleutker,et al. RAD51C is a susceptibility gene for ovarian cancer. , 2011, Human molecular genetics.
[15] A. Mannermaa,et al. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility , 2011, Breast Cancer Research and Treatment.
[16] Yuntao Xie,et al. RAD51C germline mutations in Chinese women with familial breast cancer , 2011, Breast Cancer Research and Treatment.
[17] P. Pérez-Segura,et al. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families , 2011, Breast Cancer Research and Treatment.
[18] R. Scott,et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer , 2011, Breast Cancer Research and Treatment.
[19] D. Palli,et al. Mutation screening of RAD51C in male breast cancer patients , 2011, Breast Cancer Research.
[20] P. Sung,et al. Enhancement of the RAD51 Recombinase Activity by the Tumor Suppressor PALB2 , 2010, Nature Structural &Molecular Biology.
[21] Marc Tischkowitz,et al. RAD51C germline mutations in breast and ovarian cancer patients , 2010, Breast Cancer Research.
[22] Jing Zhang,et al. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer , 2010, Breast Cancer Research and Treatment.
[23] Dieter Niederacher,et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.
[24] Franca Fraternali,et al. Mutation of the RAD51C gene in a Fanconi anemia–like disorder , 2010, Nature Genetics.
[25] S. Seal,et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.
[26] Nazneen Rahman,et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.
[27] C Eng,et al. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome , 2004, Journal of Medical Genetics.
[28] P. Oefner,et al. Contributions of ATM mutations to familial breast and ovarian cancer. , 2003, Cancer research.
[29] Nazneen Rahman,et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.
[30] S C West,et al. Identification and purification of two distinct complexes containing the five RAD51 paralogs. , 2001, Genes & development.
[31] D. Schild,et al. Mutants of the Five Rad51 Paralogs Recombinational Repair in Knockout Chromosome Instability and Defective , 2022 .
[32] J. Fraumeni,et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[33] S. Seal,et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.
[34] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[35] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[36] M. Swift,et al. Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.
[37] The Polish Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .